Middle East and Africa Internal Neurostimulation Devices Market, By Product Type (Spinal Cord Stimulation (SCS), Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation and Gastric Electric Stimulation), Distribution Channel (Direct Tender and Third Party Service Provider) - Industry Trends and Forecast to 2029
Middle East and Africa Internal Neurostimulation Devices Market Analysis and Insights
The rise in demand for internal neurostimulation devices as add-on therapy, increase in prevalence and incidence of neurological diseases, increased funding for the neurostimulation devices, technological advancements in the internal neurostimulation devices, and rise in product approvals are expected to drive market growth.
The strategic initiatives by market players and increased funding by public and private market players for internal neurostimulation devices are expected to create opportunities for market growth. However, the lack of skilled and trained experts in internal neurostimulation devices is expected to restrain the segment's growth. The availability of alternate imaging devices is expected to challenge the market growth.
Data Bridge Market Research analyzes that the Middle East and Africa internal neurostimulation devices market will grow at a CAGR of 9.6% and USD 1,397.00 Million during the forecast period of 2022 to 2029.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2024)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Product Type (Spinal Cord Stimulation (SCS), Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation and Gastric Electric Stimulation), Distribution Channel (Direct Tender and Third Party Service Provider)
|
|
Countries Covered
|
South Africa, U.A.E, Egypt, Saudi Arabia, Israel, Rest of the Middle East and Africa
|
|
Market Players Covered
|
Medtronic, LivaNova PLC, Abbott, Microsemi (a subsidiary of Microchip Technology Inc.), Boston Scientific Corporation, BlueWind Medical, Valencia Technologies, and Sequana Medical NV, among others
|
Market Definition
An internal neurostimulation device is a surgically placed device. It delivers mild electrical signals to the epidural space near your spine through one or more thin wires called leads. Neurostimulation provides pain relief by disrupting the pain signals traveling between the spinal cord and the brain.
Neurostimulation devices include invasive and noninvasive approaches involving electrical stimulation to drive neural function within a circuit. The increased demand for internal neurostimulation devices is due to next-generation technological progressions in the neurostimulation devices, providing much-needed therapeutic relief to an unprecedented number of people affected by debilitating neurologic and psychiatric disorders worldwide. The rise of modern-day neuromodulation therapies has increased over half a century, rich with serendipitous discoveries and technological advances that have led to different neurostimulation strategies. Within the past two decades, innovation in medical device technology has begun to drive the evolution of these neurostimulation systems at a more accelerated pace
The convenient internal neurostimulation device used by the patients is vagus nerve stimulation. The vagus neurostimulation device uses a device to stimulate the vagus nerve with electrical impulses. An implantable vagus nerve stimulator is currently FDA-approved to treat epilepsy and depression. There's one vagus nerve on each side of the body, running from the brainstem through the neck to the chest and abdomen. In the future, software advancements such as closed-loop stimulation and remote programming will enable internal neurostimulation devices to be a more personalized and accessible technology. The future of internal neurostimulation devices is expected to improve quality of life further.
Middle East and Africa Internal Neurostimulation Devices Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Increased Awareness About Treatment of Chronic Urinary Incontinence
Increasing awareness among patients and health care providers and greater access to continence services were key factors in improving care delivery. Urinary incontinence (UI) and lower urinary tract symptoms (LUTS) are common and are a great cause of distress for many women and men of all ages in Africa.
For instance,
- In June 2022, according to the data by Plos Global Public Health, 21% of women in Sub-Saharan Africa (SSA) have some form of urinary incontinence. This implies that there is the need to increase public health education and create awareness among people to promote health-seeking behaviors among women
The increased awareness of implant internal neurostimulation devices in neurology signifies the increase in research and development-related investments for the discovery and development of advanced, pain-free internal neurostimulation devices, which is expected to boost market growth.
- Rise In Product Approvals
The approval for the internal neurostimulation devices is governed by the U.S. Food and Drug Administration (FDA) and the European Union. The Food and Drug Administration (FDA) issues a final protocol for filing a premarket approval application (PMA) or a notice of completion of a product development protocol (PDP). The European Union certifies internal neurostimulation devices.
For instance,
- In May 2022, Micro-Leads received the Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval for the spinal cord stimulation system. The approval received would allow Micro-Leads to check the safety and efficacy of the 60-electrode spinal cord stimulator system in humans
The approval for the internal neurostimulation devices would result in the device being declared safe to use and ready for post-marketing approval. It would result in the supply and distribution of MRI machines to the developing markets in Europe and the U.S. demographics. Hence, the rise in product approvals is expected to propel the Middle East and Africa internal neurostimulation devices market growth.
Opportunities
- Strategic Initiatives by Market Players
The demand for internal neurostimulation devices is increasing in the market owing to the research and development and the growth of the internal neurostimulation devices market aided by the desire for innovative medications. Thus, the top market players have implemented a new strategy by developing new devices and equipment, collaborating with other players in the market, and improving business operations and profitability.
For instance,
- In January 2021, Boston Scientific began shipping their Wave Writer Alpha spinal line trigger frameworks to the U.S.
- In May 2019, Abbott Laboratories partnered with NIH on the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative to accelerate advancements in neurological science
Thus, the companies operating globally in the neurostimulation devices market are adopting collaboration to increase their product portfolio with advanced technology-rich products to boost their business in various dimensions. Thus, strategic initiatives by key market players are expected to offer significant opportunities for the market players operating in the Middle East and Africa internal neurostimulation devices market.
- Demand for Minimally Invasive Surgery
During minimally invasive surgery, one or more small incisions may be created on the body. A laparoscope—narrow, tube-like equipment with a light and a viewing lens—is placed into one orifice to direct the procedure. Tiny surgical instruments are placed into other incisions to perform the surgery. Therefore, such procedures are utilized to treat neurostimulation diseases to control chronic pain without danger or adverse effects. Moreover, the Middle East and Africa internal neurostimulation devices market has a vast potential to upgrade various applications. There are high chances of advancing neurostimulation devices in the forecast period.
- In March 2022, DSM Biomedical and Svelte Medical Systems, a privately-held company engaged in developing highly deliverable balloon expandable stents, have revolutionized the standard for coronary stenting procedures to treat coronary artery disease (CAD)
The surge in demand for noninvasive surgery would result in fewer human resources and swift diagnosis and recovery of chronic neurological diseases. This aspect will become a driving force for the Middle East and Africa internal neurostimulation devices market.
Restraints/Challenges
- Risks Associated with the Implantation of these Devices
Medical implants carry several hazards, including those related to surgery during installation or removal, infection, and implant failure. The materials used in implants can potentially cause responses in some persons. Every surgical procedure carries some risk. These include bruising, discomfort, swelling, and redness at the surgery site. Thereby will proportionally hamper the growth of implant devices. The increasing awareness about the rising risks related to neurostimulation implants, therefore, may hamper the market's growth.
For instance,
- Implant failure
- Surgical risks during placement or removal
- Risk of implantable device hijacking
- Rising infections
- Materials used in implants might show adverse reactions in patients
The risks mentioned above may hamper the growth of the Middle East and Africa internal neurostimulation devices market as the risks concerned to the patients are of keen importance. Thus, the awareness of the potential risks of implantable devices acts as a challenge for the Middle East and Africa internal neurostimulation devices market.
- Lack of Skilled Healthcare Professionals
Neurostimulation devices are implantable, programmable medical devices that deliver electrical stimulation to specific parts of the patient's brain, spinal cord, or peripheral nervous system to help treat various conditions, including chronic pain, movement disorders, epilepsy, and Parkinson's disease. These powerful technologies require a high-cost developmental procedure and skilled professionals to handle sensitive devices. The replacement should be done every 3-6 years after implantation, which is a cost burden and is typically out of pocket for most patients.
Only a relatively small number of patients in poorer nations can afford neurological therapy due to high prices, a weak reimbursement environment, and a lack of skilled healthcare resources. As a result, healthcare facilities are hesitant to spend money on novel or cutting-edge technology, limiting the expansion of the Middle East and Africa internal neurostimulation devices market. Thus, these challenges may hamper the growth of the market.
COVID-19 Impact on the Middle East and Africa Internal Neurostimulation Devices Market
During the pandemic, the Middle East and Africa internal neurostimulation devices sector focuses on using a combination of biology and information technology. During the COVID-19 pandemic, new therapeutic challenges have been added to the usual ones in the internal neurostimulation devices. Patients with an implantable device for intrathecal infusion need a refill of the pump to avoid abstinence syndrome. Patients with neurostimulation implants can need checkups in case of infection, wound dehiscence, or lead migration.
Recent Developments
- In January 2022, Medtronic received product approval from the Food and Drug Administration (FDA) for Intellis rechargeable neurostimulator, a spinal cord stimulation therapy for treating chronic pain resulting from diabetic peripheral neuropathy. The product approval received resulted in the addition of a new product in the spinal cord stimulation product category. The approval is expected for post-market approval in the U.S. market
- In July 2022, Abbott received approval from the Food and Drug Administration (FDA) for the Infinity deep brain stimulation system to treat depression. The approval received resulted in the rise in the initiation of pre and post-marketing approval and the addition of a new product to the product portfolio
Middle East and Africa Internal Neurostimulation Devices Market Scope
Middle East and Africa internal neurostimulation devices market is categorized into product type and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Spinal Cord Stimulation (SCS)
- Deep Brain Stimulation
- Vagus Nerve Stimulation
- Sacral Nerve Stimulation
- Gastric Electric Stimulation
On the basis of product type, the Middle East and Africa internal neurostimulation devices market is segmented into spinal cord stimulation (SCS), deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, gastric electric stimulation.
Distribution Channel
- Direct Tender
- Third Party Service Provider
On the basis of distribution channel, the Middle East and Africa internal neurostimulation devices market is segmented into direct tender and third party service provider.
Middle East and Africa Internal Neurostimulation Devices Market Regional Analysis/Insights
Middle East and Africa internal neurostimulation devices market is analyzed, and regions provide market size insights and trends, product type, and distribution channel as referenced above.
Some countries covered in the Middle East and Africa internal neurostimulation devices market are South Africa, U.A.E, Egypt, Saudi Arabia, Israel, Rest of the Middle East and Africa. South Africa is expected to dominate the market due to a rise in research and development activity, the surging demand for advanced neurostimulation devices, and the wide product portfolio offered by major market players and product developments.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of the Middle East and African brands and their challenges faced due to large or scarce competition from local and domestic brands impact sales channels. They are also considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Internal Neurostimulation Devices Market Share Analysis
Middle East and Africa internal neurostimulation devices market competitive landscape provides details on the competitor. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, the Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the Middle East and Africa internal neurostimulation devices market.
Some of the major players operating in the Middle East and Africa internal neurostimulation devices market are Medtronic, LivaNova PLC, Abbott, Microsemi (a subsidiary of Microchip Technology Inc.), Boston Scientific Corporation, BlueWind Medical, Valencia Technologies, and Sequana Medical NV, among others.
SKU-